| Scrip Code | 544222 |
|---|---|
| NSE Symbol | AKUMS |
| MSEI Symbol | NOTLISTED |
| ISIN | INE09XN01023 |
| Name of company | Akums Drugs and Pharmaceuticals Limited |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2026 |
| Date of end of financial year | 31-03-2027 |
| Date of board meeting when results were approved | 08-08-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 05-08-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | First quarter |
| Nature of report standalone or consolidated | Consolidated |
| Whether results are audited or unaudited for the quarter ended | Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | |
| Segment Reporting | Multi segment |
| Description of single segment | |
| Start date and time of board meeting | 08-08-2026 13:30:00 |
| End date and time of board meeting | 08-08-2026 15:15:00 |
| Whether cash flow statement is applicable on company | |
| Type of cash flow statement | |
| Declaration of unmodified opinion or statement on impact of audit qualification | Not applicable |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-04-2026 | 01-04-2026 |
| B | Date of end of reporting period | 30-06-2026 | 30-06-2026 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| 1 | Income | ||
| Revenue from operations | 1,16,662.90 | 1,16,662.90 | |
| Other income | 3,038.00 | 3,038.00 | |
| Total income | 1,19,700.90 | 1,19,700.90 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 68,212.40 | 68,212.40 |
| (b) | Purchases of stock-in-trade | 2,648.80 | 2,648.80 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | (6,318.90) | (6,318.90) |
| (d) | Employee benefit expense | 20,143.30 | 20,143.30 |
| (e) | Finance costs | 2,475.60 | 2,475.60 |
| (f) | Depreciation, depletion and amortisation expense | 4,106.50 | 4,106.50 |
| (f) | Other Expenses | ||
| 1 | Other Expenses | 14,509.50 | 14,509.50 |
| Total other expenses | 14,509.50 | 14,509.50 | |
| Total expenses | 1,05,777.20 | 1,05,777.20 | |
| 3 | Total profit before exceptional items and tax | 13,923.70 | 13,923.70 |
| 4 | Exceptional items | 0.00 | 0.00 |
| 5 | Total profit before tax | 13,923.70 | 13,923.70 |
| 6 | Tax expense | ||
| 7 | Current tax | 2,715.00 | 2,715.00 |
| 8 | Deferred tax | 1,110.90 | 1,110.90 |
| 9 | Total tax expenses | 3,825.90 | 3,825.90 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | 10,097.80 | 10,097.80 |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 |
| 16 | Total profit (loss) for period | 10,097.80 | 10,097.80 |
| 17 | Other comprehensive income net of taxes | 311.20 | 311.20 |
| 18 | Total Comprehensive Income for the period | 10,409.00 | 10,409.00 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | 10,001.00 | 10,001.00 | |
| Total profit or loss, attributable to non-controlling interests | 96.80 | 96.80 | |
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | 10,313.00 | 10,313.00 | |
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | 96.00 | 96.00 | |
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 3,062.10 | 3,062.10 | |
| Face value of equity share capital | 2 | 2 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 6.53 | 6.53 | |
| Diluted earnings (loss) per share from continuing operations | 6.53 | 6.53 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 6.53 | 6.53 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 6.53 | 6.53 | |
| 24 | Debt equity ratio | 0 | 0 |
| 25 | Debt service coverage ratio | 0 | 0 |
| 26 | Interest service coverage ratio | 0 | 0 |
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | For detailed notes, please refer the unaudited financial results uploaded on stock exchanges in pdf format on 08.08.2026 |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-04-2026 | 01-04-2026 | |||||
| Date of end of reporting period | 30-06-2026 | 30-06-2026 | |||||
| Whether results are audited or unaudited | Unaudited | Unaudited | |||||
| Nature of report standalone or consolidated | Consolidated | Consolidated | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| 1 | CDMO | 96,421.20 | 96,421.20 | ||||
| 2 | API | 3,164.60 | 3,164.60 | ||||
| 3 | Domestic branded formulations | 11,527.90 | 11,527.90 | ||||
| 4 | International branded formulations | 3,454.80 | 3,454.80 | ||||
| 5 | Trade generics | 2,094.40 | 2,094.40 | ||||
| 6 | Inter-segment eliminations | 0.00 | 0.00 | ||||
| Total Segment Revenue | 1,16,662.90 | 1,16,662.90 | |||||
| Less: Inter segment revenue | 0.00 | 0.00 | |||||
| Revenue from operations | 1,16,662.90 | 1,16,662.90 | |||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| 1 | CDMO | 12,652.80 | 12,652.80 | ||||
| 2 | API | (814.60) | (814.60) | ||||
| 3 | Domestic branded formulations | 1,083.40 | 1,083.40 | ||||
| 4 | International branded formulations | 621.50 | 621.50 | ||||
| 5 | Trade generics | 1.20 | 1.20 | ||||
| 6 | Inter-segment eliminations | 0.00 | 0.00 | ||||
| Total Profit before tax | 13,544.30 | 13,544.30 | |||||
| i. Finance cost | 2,285.60 | 2,285.60 | |||||
| ii. Other Unallocable Expenditure net off Unallocable income | (2,665.00) | (2,665.00) | |||||
| Profit before tax | 13,923.70 | 13,923.70 | |||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| 1 | CDMO | 3,31,819.30 | 3,31,819.30 | ||||
| 2 | API | 37,395.50 | 37,395.50 | ||||
| 3 | Domestic branded formulations | 9,231.00 | 9,231.00 | ||||
| 4 | International branded formulations | 9,364.90 | 9,364.90 | ||||
| 5 | Trade generics | 4,145.90 | 4,145.90 | ||||
| 6 | Inter-segment eliminations | (8,754.80) | (8,754.80) | ||||
| Total Segment Asset | 3,83,201.80 | 3,83,201.80 | |||||
| Un-allocable Assets | 1,87,152.20 | 1,87,152.20 | |||||
| Net Segment Asset | 5,70,354.00 | 5,70,354.00 | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| 1 | CDMO | 1,93,895.20 | 1,93,895.20 | ||||
| 2 | API | 4,465.80 | 4,465.80 | ||||
| 3 | Domestic branded formulations | 13,130.60 | 13,130.60 | ||||
| 4 | International branded formulations | 5,412.00 | 5,412.00 | ||||
| 5 | Trade generics | 3,754.80 | 3,754.80 | ||||
| 6 | Inter-segment eliminations | (8,754.80) | (8,754.80) | ||||
| Total Segment Liabilities | 2,11,903.60 | 2,11,903.60 | |||||
| Un-allocable Liabilities | 14,929.30 | 14,929.30 | |||||
| Net Segment Liabilities | 2,26,832.90 | 2,26,832.90 | |||||
| Disclosure of notes on segments | Textual Information(2) | ||||||
| Textual Information(2) | * Segment results before depreciation are computed by aggregating profit/ (loss) before tax, exceptional items, finance costs, and depreciation and amortisation expense, and deducting interest income and other unallocated income/ (expenses) [net]. ** Segment results is calculated as segment results before depreciation less finance costs pertaining to segments and depreciation and amortisation expense. |
|---|
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-04-2026 | 01-04-2026 |
| B | Date of end of reporting period | 30-06-2026 | 30-06-2026 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Remeasurements of defined benefit plans | 390.90 | 390.90 |
| Total Amount of items that will not be reclassified to profit and loss | 390.90 | ||
| 2 | Income tax relating to items that will not be reclassified to profit or loss | 79.80 | 79.80 |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| 1 | Exchange differences on translation of foreign operations | 0.10 | 0.10 |
| Total Amount of items that will be reclassified to profit and loss | 0.10 | ||
| 4 | Income tax relating to items that will be reclassified to profit or loss | 0.00 | 0.00 |
| 5 | Total Other comprehensive income | 311.20 | 311.20 |